دورية أكاديمية
Severe Acute Respiratory Syndrome Coronavirus 2 Infection History and Antibody Response to 3 Coronavirus Disease 2019 Messenger RNA Vaccine Doses.
| العنوان: | Severe Acute Respiratory Syndrome Coronavirus 2 Infection History and Antibody Response to 3 Coronavirus Disease 2019 Messenger RNA Vaccine Doses. |
|---|---|
| المؤلفون: | Herring MK; Abt Associates, Rockville, Maryland, USA., Romine JK; Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, Arizona, USA., Wesley MG; Abt Associates, Rockville, Maryland, USA., Ellingson KD; Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, Arizona, USA., Yoon SK; Rocky Mountain Center for Occupational and Environmental Health, University of Utah Health, Salt Lake City, Utah, USA., Caban-Martinez AJ; University of Miami, Miller School of Medicine, Miami, Florida, USA., Meece J; Marshfield Clinic, Marshfield, Wisconsin, USA., Gaglani M; Baylor Scott and White Health, Temple, Texas, USA.; Texas A&M University College of Medicine, Temple, Texas, USA., Grant L; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Olsho LEW; Abt Associates, Rockville, Maryland, USA., Tyner HL; St. Luke's Regional Health Care System, Duluth, Minnesota, USA., Naleway AL; Kaiser Permanente Northwest Center for Health Research, Portland, Oregon, USA., Khan SM; Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, Arizona, USA., Phillips AL; Rocky Mountain Center for Occupational and Environmental Health, University of Utah Health, Salt Lake City, Utah, USA., Solle NS; University of Miami, Miller School of Medicine, Miami, Florida, USA., Rose S; Baylor Scott and White Health, Temple, Texas, USA., Mak J; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Fuller SB; Abt Associates, Rockville, Maryland, USA., Hunt A; St. Luke's Regional Health Care System, Duluth, Minnesota, USA., Kuntz JL; Kaiser Permanente Northwest Center for Health Research, Portland, Oregon, USA., Beitel S; Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, Arizona, USA., Yoo YM; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Zheng PQ; Abt Associates, Rockville, Maryland, USA., Arani G; Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, Arizona, USA., Lamberte JM; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Edwards T; University of Arizona Genetics Core, Office for Research, Innovation and Impact, University of Arizona, Tucson, Arizona, USA., Thompson MG; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Sprissler R; University of Arizona Genetics Core, Office for Research, Innovation and Impact, University of Arizona, Tucson, Arizona, USA., Thornburg NJ; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Lowe AA; Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, Arizona, USA., Pilishvili T; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Uhrlaub JL; Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, Arizona, USA., Lutrick K; College of Medicine-Tucson, University of Arizona, Tucson, Arizona, USA., Burgess JL; Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, Arizona, USA., Fowlkes AL; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. |
| المصدر: | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2023 May 24; Vol. 76 (10), pp. 1822-1831. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. |
| اللغة: | English |
| بيانات الدورية: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 9203213 Publication Model: Print Cited Medium: Internet ISSN: 1537-6591 (Electronic) Linking ISSN: 10584838 NLM ISO Abbreviation: Clin Infect Dis Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Jan. 2011- : Oxford : Oxford University Press Original Publication: Chicago, IL : The University of Chicago Press, c1992- |
| مواضيع طبية MeSH: | COVID-19 Vaccines* , COVID-19*/prevention & control, Humans ; Antibody Formation ; SARS-CoV-2 ; RNA, Messenger ; mRNA Vaccines ; Antibodies, Viral |
| مستخلص: | Background: Data on antibody kinetics are limited among individuals previously infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). From a cohort of healthcare personnel and other frontline workers in 6 US states, we assessed antibody waning after messenger RNA (mRNA) dose 2 and response to dose 3 according to SARS-CoV-2 infection history. Methods: Participants submitted sera every 3 months, after SARS-CoV-2 infection, and after each mRNA vaccine dose. Sera were tested for antibodies and reported as area under the serial dilution curve (AUC). Changes in AUC values over time were compared using a linear mixed model. Results: Analysis included 388 participants who received dose 3 by November 2021. There were 3 comparison groups: vaccine only with no known prior SARS-CoV-2 infection (n = 224); infection prior to dose 1 (n = 123); and infection after dose 2 and before dose 3 (n = 41). The interval from dose 2 and dose 3 was approximately 8 months. After dose 3, antibody levels rose 2.5-fold (95% confidence interval [CI] = 2.2-3.0) in group 2 and 2.9-fold (95% CI = 2.6-3.3) in group 1. Those infected within 90 days before dose 3 (and median 233 days [interquartile range, 213-246] after dose 2) did not increase significantly after dose 3. Conclusions: A third dose of mRNA vaccine typically elicited a robust humoral immune response among those with primary vaccination regardless of SARS-CoV-2 infection >3 months prior to boosting. Those with infection <3 months prior to boosting did not have a significant increase in antibody concentrations in response to a booster. Competing Interests: Potential conflicts of interest. A. L. N. reports research funding from Pfizer and Vir Biotechnology for unrelated studies. A. J. C.-M. reports Federal Emergency Management Agency grants (EMW-2019-FP-00526, EMW-2019-FP-00517, and EMW-2017-FP-00860) and State of Florida Appropriation 2369A and 2369A. M. G. reports grants or contracts unrelated to this work from the CDC–Abt Associates, CDC, CDC–VUMC, CDC–Westat and a role as co-chair of the Infectious Diseases and Immunization Committee, Texas Pediatric Society, Texas Chapter of the American Academy of Pediatrics. A. A. L. reports grants or contracts from Mercy C.A.R.E.S., National Heart Lung and Blood Institute, and the US Environmental Protection Agency and a leadership or fiduciary role with the Arizona Asthma Coalition. R. S. and J. L. U. report patents planned, issued, or pending (serological assays for SARS-CoV-2). All other authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. (© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.) |
| معلومات مُعتمدة: | 75D30120C08379 United States CC CDC HHS; 75D30120C08150 United States CC CDC HHS |
| فهرسة مساهمة: | Keywords: COVID-19; antibody kinetics; antibody response; booster; mRNA vaccine |
| المشرفين على المادة: | 0 (COVID-19 Vaccines) 0 (RNA, Messenger) 0 (mRNA Vaccines) 0 (Antibodies, Viral) |
| تواريخ الأحداث: | Date Created: 20221229 Date Completed: 20230526 Latest Revision: 20230530 |
| رمز التحديث: | 20230530 |
| DOI: | 10.1093/cid/ciac976 |
| PMID: | 36578137 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1537-6591 |
|---|---|
| DOI: | 10.1093/cid/ciac976 |